Search
Ranitidine
go.drugbank.com/drugs/DB00863ApprovedWithdrawnRanitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulc...
Products: Ranitidine Non Prescription, Zantac Maximum Strength Non-prescriptionLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalLifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through...
Phenserine
go.drugbank.com/drugs/DB04892InvestigationalPhenserine is under development by Axonyx, a US biopharmaceutical company that focuses on treatments for dementia. … Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials.
Povidone
go.drugbank.com/drugs/DB11061ApprovedInvestigationalWithdrawnThe clinical effectiveness of [DB06812] on wound healing remains somewhat controversial, as it was demonstrated in a few clinical studies that the application of the compound in wounds was associated with
Lunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational[A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet.
Milrinone
go.drugbank.com/drugs/DB00235ApprovedInvestigational[A228333] It was approved by the FDA on December 31, 1987, and was marketed under the trademark PRIMACOR® by Sanofi-Aventis US before being discontinued.[L31483]
Sacubitril
go.drugbank.com/drugs/DB09292ApprovedInvestigationalIt was approved by the FDA after being given the status of priority review for on July 7, 2015.
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]